NeuroSense Therapeutics Ltd. (NRSN) announced on Monday the positive results from the 12-month data analysis of the PARADIGM Phase 2b study, which evaluates PrimeC in patients with Amyotrophic Lateral Sclerosis (ALS)—a neurodegenerative disease without a cure.
The trial demonstrated a 35% reduction in disease progression in participants treated with PrimeC, a fixed-dose combination of FDA-approved ciprofloxacin and celecoxib, over 12 months, compared to those who received a placebo.
Additionally, the company reported that PrimeC-treated participants had a higher survival rate at the 12-month mark compared to those who were initially on placebo.
NeuroSense plans to initiate a Phase 3 clinical study in both the U.S. and Europe.
As of now, NeuroSense's stock is down 8.05%, trading at $1.029 on the Nasdaq.
